360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Les Laboratoires SERVIER

Type: Company

Name: Les Laboratoires SERVIER

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Warner Chilcott plc

Merck Stops Development of Parkinson$s Drug

05/23/2013 French Drugmaker on Trial for Suspected DeathsFrom Yahoo! NewsServier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds ... [Published Pharmaceutical Manufacturing Magazine - May 24 2013]

Entities: Camfil, Warner Chilcott plc, Drugs, Actavis, Xellia Pharmaceuticals AS

First reported May 24 2013 - Updated May 24 2013 - 2 reports

miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier

Servier selects third cardiovascular target triggering the first milestone under the collaboration. ... [Published Technology Networks - May 24 2013]

Entities: Les Laboratoires SERVIER, Therapeutics

First reported May 24 2013 - Updated May 24 2013 - 1 reports

[World Report] Mediator scandal engulfs French compensation body

The national organisation responsible for compensating patients harmed by benfluorex in France may be denying too many claims. Asher Mullard reports. In December, 2009, French drug regulators withdrew Servier's Mediator (benfluorex) because the antidiabetic, ... [Published Lancet - May 24 2013]

Entities: The Lancet, Les Laboratoires SERVIER, Patient

First reported May 23 2013 - Updated May 23 2013 - 1 reports

French Drugmaker on Trial for Suspected Deaths

Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people. ... [Published Pharmaceutical Manufacturing Magazine - May 23 2013]

Entities: Les Laboratoires SERVIER, Deception, Weight Loss

First reported May 21 2013 - Updated May 21 2013 - 2 reports

France Drugmaker on trial suspected in deaths

France: Drugmaker on trial, suspected in deathsNANTERRE, France -- A French drug company and its founder are on trial on charges of misleading the public about a diabetes drug marketed as a weight loss method and suspected in hundreds of deaths.But after ... [Published Birmingham Star - May 21 2013]

Entities: France, Nanterre (France), Cannes (France), Weight Loss

First reported May 21 2013 - Updated May 21 2013 - 3 reports

FRANCE: French killer slimming drug trial opens

Jacques Servier at Nanterre courthouse TuesdayReuters/Philippe WojazerThe trial started Tuesday of bosses of a French company that marketed a drug believed to have cost up to 1,800 lives. The drug, Mediator, was often prescribed as a slimming aid, although ... [Published Radio France Internationale - May 21 2013]

Entities: Les Laboratoires SERVIER, Drugs, Valvular heart disease, France

First reported May 17 2013 - Updated May 17 2013 - 1 reports

NHS

Falls project shortlisted for national award

A local project aimed at reducing falls and fractures in care homes and preventing emergency admissions to hospital has been shortlisted in the musculoskeletal care category of the Care Integration Awards 2013.A local project aimed at reducing falls and ... [Published Elmbridge Today - May 17 2013]

Entities: musculoskeletal, emergency, Admission, NHS, Les Laboratoires SERVIER

First reported May 11 2013 - Updated May 11 2013 - 1 reports

3 Humongous Health-Care Stocks This Week

The single, easiest way to keep track of all the stocks that matter...Your own personalized stock watchlist!It's a 100% FREE Motley Fool service... Few sectors see as many stocks gaining in the double-digits each week as health care. The past week proved ... [Published Motley Fool - May 11 2013]

Entities: Phase II, Les Laboratoires SERVIER, watchlist

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Afraxis, Inc. and Servier Announce a Collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorders

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology ... [Published NewsRX - May 10 2013]

Entities: Les Laboratoires SERVIER, Central Nervous System, Drug Discovery

First reported May 09 2013 - Updated May 09 2013 - 1 reports

XOMA Corp CEO Discuses Q1 2013 Results - Earnings Call Transcript

4:30 PM ETOperatorGood afternoon, ladies and gentlemen and welcome to the XOMA Corporation’s First Quarter 2013 Financial Results Conference Call. (Operator Instructions). As a reminder today's conference is being recorded.I will now like to turn the ... [Published Seeking Alpha - May 09 2013]

Entities: Patient, Xoma Ltd, Osteoarthritis

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Afraxis, Inc. and Servier Announce a Collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorders

-- /PRNewswire/ -- Afraxis, Inc. ("Afraxis") and Institut de Recherches Servier ("Servier") announced a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology for the discovery of drugs to treat central nervous system ... [Published FierceBiotech - May 07 2013]

Entities: Les Laboratoires SERVIER, Central Nervous System, Drug Discovery

First reported Apr 30 2013 - Updated Apr 30 2013 - 3 reports

Afraxis, Servier Collaborate on Drug Discovery for CNS Disorders

Afraxis today announced it is collaborating with French pharma Servier on a drug discovery effort to treat central nervous system (CNS) disorders. The two firms will be using Afraxis' Enhanced Spine Platform (ESP) technology to assess complex neural networks ... [Published Genetic Engineering News - Apr 30 2013]

Entities: Les Laboratoires SERVIER, Drug Discovery, Central Nervous System, Therapeutics

Quotes

BioInvent’s chairman Björn O Nilsson says in a comment "We are very pleased to have been able to recruit a new CEO with a broad and international experience from different parts of the life science industry. We are confident that Michael's expertise and experience of licenses, contracts and commercial solutions and collaborations will be of great importance for our new strategic direction, which include increased focus on developing existing and new alliances with partners based on our technology platform and project portfolio."

BioInvent recruits Michael Oredsson as new CEO [Published Business Wire - May 24 2013]

...According to Monique Goyens of the European Consumer Organisation, "Over 5,000 women are seeking compensation in French courts for the harm inflicted upon them."

Verdict nears for PIP scandal [Published Riviera Times - May 21 2013]

...of this molecule for the safe treatment of rheumatoid arthritis and other inflammatory diseases," said Onno van de Stolpe, CEO of Galapagos. "In our development portfolio, we now have three programs in Phase 2 studies in four inflammation disease areas, and we are well on track to having multiple Phase 1 programs with novel, proprietary modes of action by end 2013."

Galapagos business update [Published Zecco - May 17 2013]

Referring to its commercial potential, he pointed to Waterford as the "intersection point for Ireland's bio-pharma/life sciences and ICT international services industries."

Tramore land on market for €1.5m [Published Irish Independent - May 16 2013]

More Content

sort by: Date \| Relevance
Merck Stops Development of Parkinson$s Drug [Published Pharmaceutical Manufacturing Magazine - May 24 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Technology Networks - May 24 2013]
Vernalis plc: New Vernalis plc company profile ... [Published TransWorldNews - May 24 2013]
COGSTATE LIMITED: Company Secretary Appointment [Published 4 Traders - May 24 2013]
Servier, miRagen to add third cardiovascular ta... [Published PBR - News - May 24 2013]
BioInvent recruits Michael Oredsson as new CEO [Published Business Wire - May 24 2013]
BioInvent rekryterar Michael Oredsson som ny VD [Published GlobeNewswire - May 24 2013]
[World Report] Mediator scandal engulfs French ... [Published Lancet - May 24 2013]
French Drugmaker on Trial for Suspected Deaths [Published Pharmaceutical Manufacturing Magazine - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published EON: Enhanced Online News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Science: Science News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Photo/Multimedia News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Health News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire News with Multimedia - May 23 2013]
Vernalis PLC : Result of AGM [Published Investegate - May 22 2013]
France Drugmaker on trial suspected in deaths [Published Birmingham Star - May 21 2013]
FRANCE: French killer slimming drug trial opens [Published Radio France Internationale - May 21 2013]
France: Drugmaker on trial, suspected in deaths [Published Modesto Bee - May 21 2013]
Verdict nears for PIP scandal [Published Riviera Times - May 21 2013]
France: Drugmaker on trial, suspected in deaths [Published Stamford Advocate - May 21 2013]
France: Drugmaker on trial, suspected in deaths [Published Alaska Journal - May 21 2013]
Falls project shortlisted for national award [Published Elmbridge Today - May 17 2013]
Galapagos business update [Published Zecco - May 17 2013]
Tramore land on market for €1.5m [Published Irish Independent - May 16 2013]
Most Emerging Stocks Rise as Indian Shares Rall... [Published Bloomberg - May 15 2013]
Bahrain 'free of fake medicines' [Published Individual.com - May 12 2013]
Xoma Corp (XOMA), WebMD Health Corp. (WBMD), an... [Published InsiderMonkey.com - May 11 2013]
3 Humongous Health-Care Stocks This Week [Published Motley Fool - May 11 2013]
XOMA Management Presents at Credit Suisse 2013 ... [Published Seeking Alpha - May 10 2013]
Bacterial Partnering Terms and Agreements - 201... [Published PredictWallStreet - May 10 2013]

Blogs

sort by: Date \| Relevance
Servier, miRagen to add third cardiovascular ta... [Published PBR - News - May 24 2013] Servier and miRagen Therapeutics have announced the selection of a third target under the agreement aimed at advancing the research and commercialization of microRNA-based drug candidates against cardiovascular diseases. ...
Orphan designation: Gevokizumab, for the: Treat... [Published Orphan designations - Apr 05 2013] On 12 March 2013, orphan designation (EU/3/13/1111) was granted by the European Commission to Les Laboratoires Servier, France, for gevokizumab for the treatment of chronic non-infectious uveitis. ...
French Regulator Investigated Over Servier Scandal [Published Pharmalot - Mar 22 2013] The scandal over a Servier Laboratories diabetes pill, which has been blamed for at least 500 deaths in France, has now ensnared the French regulatory agency. The ANSM has come under formal investigation for alleged involuntary manslaughter over concerns ...
Is there a cure for corporate crime in the drug... [Published PharmaGossip - Feb 08 2013] Effective enforcement of regulations requires more resources and determination to impose robust sanctionsNearly 30 years ago, Braithwaite’s Corporate Crime in the Pharmaceutical Industry showed that unethical and corrupt behaviour was endemic in the sector. ...
EU Charges J&J And Novartis With Pay-To-Delay /... [Published PharmaGossip - Jan 31 2013] In the latest bid by regulators to squash so-called pay-to-delay deals, the European Commission has filed a complaint against Johnson & Johnson and Novartis – and its Sandoz generic subsidiary – for allegedly conspiring to delay the generic introduction ...

Press Releases

sort by: Date \| Relevance
BioInvent recruits Michael Oredsson as new CEO [Published Business Wire - May 24 2013]
miRagen Therapeutics Achieves First Milestone i... [Published EON: Enhanced Online News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Science: Science News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Photo/Multimedia News - May 23 2013]
miRagen Therapeutics Achieves First Milestone i... [Published Business Wire Health News - May 23 2013]